DarshanTalks Podcast cover art

All Episodes

DarshanTalks Podcast — 347 episodes

#
Title
1

Pharmacy's Critical Role in Clinical Trial Compliance

2

The Wild Lizard Venom Origins of Ozempic

3

Unlicensed Medical Advice & The Legal Battle Over Character.AI

4

Sponsoring Cannabis Research

5

The New Era of Personal Consent Decrees

6

Why Private Membership Associations Fail FDA Scrutiny

7

The Hidden Reason Sites are Firing Recruiters

8

Don’t Let Your PI Walk Away With Your Study

9

Safe or Just "Not Dirty"? The Regulatory Gamble of Compounded Drugs

10

"Basically Employees" Isn't a Legal Category (And the OIG Knows It)

11

The Hidden Legal Risks of AI Sponsor Protocols

12

The $100M Mistake: Why AI-Generated Drugs May Not Be Patentable

13

Is AI replacing your Doctor?

14

Why the OIG Just Revolutionized Pharma Marketing (And What It Costs You)

15

6 Categories of "Bulk Data" That Could Land You in Federal Court.

16

The Utah Experiment: The Dangerous New Frontier of AI Prescribing

17

Is Your DTC Program a Kickback Trap?

18

The Hidden Death Sentence for Trial Sites

19

FDA "Screams": The Real Reason Your Snack Is At Risk

20

2 Laws More Dangerous Than HIPAA for Patient Engagement

21

"Invite-Only" Compliance Is Over: Is Your Cosmetic Company Ready?

22

Audit-Proof Your Site: The Training Gap Killing Your Contracts

23

15 Years in Prison for Marketing Fraud

24

Is your "Clinical Decision Support" tool actually an unregulated medical device?

25

The FDA’s New Political Enforcement Strategy

26

Why Your "Physician-Only" Ads Aren't Safe from Regulators

27

The Messy Reality of AI Prescriptions

28

Why Your Consultant’s Report Is a Legal Liability

29

Stop Reporting Results? The NIH’s "Get Out of Jail Free" Card

30

Final LGBTQ Individuals in clinical research

31

When the FDA Plays Politics

32

Your Site’s Background Check is Illegally Incomplete - Here is why

33

Is Your Off-Label Use Now a Federal Crime?

34

10,000 Specialists: A Futurist’s Vision for AI Healthcare

35

The Battle Over Weight Loss and Compounded Drugs

36

Why Cosmetic Ingredient Names Matter and What MOCRA Really Means - Interview with Heather Bustos

37

Compliance Isn’t a Deal Killer… Until It Is - Interview with Stephanie Trunk

38

Cosmetic ingredients the FDA doesn’t want you to use

39

Why Federal Agencies Are Targeting Executives

40

Why the New Food Pyramid Matters to You

41

Ex FDA Commissioner Robert Califf on FDA Authority, Politics, and the Health Crisis No One Wants to Name

42

Buying a Med Spa? GLP-1 Compliance Can Kill the Deal

43

New crown jewel valuing patient data

44

Your Staff is trained, but can you prove it?

45

What Happens When a Sponsor Walks Away Early?

46

Cosmetic Claims the FDA Hates

47

Biggest Legal Mistakes in Influencer Marketing

48

Your Mood, Energy, and Sleep Claims Might Be Regulated

49

Device Fail: The Legal Anatomy of a Faulty Implant Scandal

50

5 Documents the FDA Will Demand on Site — Are You Ready?

51

Cosmetic Marketing Mistakes That Trigger Regulators

52

Why Your Clinical Trial Contract Is Leaving Cash on the Table

53

Why Testimonials Can Get Your Brand Sued

54

How to Get Sponsors to Pay Faster than Net 90

55

Compliance Mistakes That Kill Pharma and Biotech Deals

56

Balance FDA Rules with FTC Advertising Requirements

57

Key Clauses in PI Contracts to Review

58

Compliance guru talks practical Insights on Speaker Programs

59

Trends in Small Life Sciences Transactions

60

Protect Your Site If a Sponsor Terminates Early

61

Are Pharma Chatbots Putting You at Regulatory Risk?

62

Are Your Cosmetic Company Records Ready for FDA Audits?

63

When Medical Affairs Becomes Commercial in Disguise

64

Serious Adverse Event Reporting Under MoCRA

65

Key SOPs for Clinical Trials

66

Payer Presentations Can Trigger Enforcement

67

Pharmacies v manufacturers

68

Is Clinical Research Ready for the new FDA?

69

Is your cosmetics company FDA-registered?

70

Will AI Replace Doctors in clinical research?

71

Risks in Direct-to-Patient Engagement

72

Inside 340B: Challenges, Controversies, and Opportunities

73

IRBs in 2025: What’s Really Changing?

74

3 Red Flags in Telemedicine Partnerships

75

What do PBMs do?

76

How AMCs Build Stronger Compliance Cultures Together

77

How One DME Scheme Cost Medicare $61 Million

78

FDA to Step Up Enforcement on Pharma Advertising

79

Top 5 Factors Determining AMC Funding

80

New Series Drop: Exploring AMCs in Clinical Research

81

Why Choose a Licensed Attorney Over a Consultant?

82

Marketing Problems by Hims & Hers and Lilly

83

Should Sponsors Share Site Feedback?

84

AI Marketing Playbook for Drug Companies

85

Should Sites Be Ready on Standby?

86

Eastern District of PA Targets Pharmacies

87

Telehealth Done Right

88

DOJ and HHS Launch FCA Fraud Task Force

89

Should Sponsors Cover Malpractice Insurance?

90

Instagram Post that Sparked FDA Warning Letter

91

Why Are So Many Doctors Getting Arrested?

92

How to Run Compliant Pharma Speaker Programs

93

​​Are You Picking the Wrong KOLs?

94

How KLF’s Client Base Evolved Over 20 Years

95

FDA Pushback on Accelerated Gene Therapy Approvals

96

Your DEI Program Could Trigger an FCA Case

97

Teva’s Charity Partnership Scrutinized

98

Is There a “Right” Way to Calculate FMV?

99

Can Non-Physicians Own Clinical Trial Sites?

100

The KLF Story You Haven’t Heard

101

Why Telehealth Platforms Are Getting Sued

102

Should Clinical Trial Sites Be Paid Differently?

103

How to Build an AI Compliance Program

104

What the Big Beautiful Bill Means for Trial Sites

105

Co-Pay Mistakes Can Trigger DOJ Action

106

NIH Grant Denials Ruled Discriminatory?

107

Are Speaker programs supposed to be salesy?

108

DTP Compliance Just Got Tricky

109

Should You Use AI to Draft Informed Consent?

110

Could You Survive a Surprise Pharmacy Audit?

111

Self-Reporting in Clinical Trials

112

$14M Fine Says This “Free” Offer Wasn’t Legal

113

Nonprofit Pharma Exists. Here is how it works

114

FTC Rules for Pharma Companies

115

Whistleblowing in Clinical Trials: Is It Worth the Risk?

116

The Right Way to Do Medical Affairs on LinkedIn

117

Are We Paying Clinical Trial Patients Enough?

118

Pharma Ads Are Getting Canceled

119

Unpacking Screen Fail Payments in Research

120

Post-Trump Antitrust Rules Are Crushing Pharma Deals

121

7 Must-Know Steps to transfer medical device ownership

122

Responding to Site Findings

123

Is Your Medical Website Illegal?

124

Price Fixing in Clinical Research

125

DOJ Cracks Down on Pharmacy Fraud

126

Protect Your DTP Strategy

127

AI Clinical Trial Negotiators

128

SOPs: How Many is Too Many?

129

Is DTP Pharma’s Next Big Move?

130

Hackers Are Stealing Your Personal Health Data

131

How a “Medical Education” Program Became a $202M Fraud

132

Webinar Recap: What Sponsors Must Know About Fraud

133

AI-Powered Engagement is a Minefield

134

Webinar Update: Fraud Prevention Strategies Every Sponsor Needs

135

Are Your Promotional Claims Putting Your Company at Risk?

136

Privacy Dangers Lurking in Clinical Trial Mergers

137

The FDA's Crisis Is Now Your Problem

138

Broken FDA, Big Consequences

139

You are now the Healthcare Provider - The Future of Health Insurance: Trends, Challenges, and Innovations

140

Essential Due Diligence Steps for Clinical Research M&A

141

Is AI Telemarketing Strategy Illegal?

142

No Clinical Trial Waste

143

The Real Meaning of Audit-Readiness in Clinical Research

144

Ordinary People Are Changing Medicine

145

Investor Influence Can Trigger FCA Violations

146

Sponsor to Organization vs. Direct Investigator Agreements: Pros & Cons

147

Clinical Trial Site M&A: What Most Get Wrong

148

Future-Proof Sites: SOS Insights Revealed

149

Why Food M&A Deals Collapse—And How to Prevent It

150

Non-Compliance Led to QOL Medical's $47M Settlement

151

FDA Regulatory Submissions: Challenges, Trends, and Future Predictions

152

How to do a VR promo check - Carly Schaecter gives us her advice

153

Diversity Matters in Clinical Trials

154

EMA’s LLM Guidelines Impact Life Sciences

155

How to Network Like a Pro at Conferences

156

Getting Ready for SOS 2025: FDA 483s, SOPs, and Site Survival

157

Maximizing Site Value

158

5 Key Areas to Review in Clinical Trial Agreements

159

Discussing Stem Cell Research Opportunities with a Research Site Owner

160

Quality Management: A Must in Clinical Trial Contracts

161

AI-Powered Chatbots in Pharma Sales and Education

162

Will New Tariffs Disrupt Your Next Pharma Deal?

163

Protecting Patient Data in a Changing Regulatory Landscape

164

Off-Label Promotion Changes in 2025

165

Turning Physicians into Leaders

166

Key Regulatory Agencies in Pharma M&A

167

Does E6 (R3) Blur the Line Between GCP and Privacy Laws?

168

RFK Jr. Confirmed as HHS Secretary: What It Means for Healthcare Policy

169

America’s Research Future in Jeopardy

170

Trump Administration’s NIH cuts: Will they cripple US medical research?

171

DEI Under Trump: What It Means for Clinical Trials

172

CAPA & RCA: A Must for Pharma M&A

173

Trump Targets Indirect Costs in NIH Funding

174

The USAID Halt and Its Consequences for Clinical Research

175

Ebola Vaccine Trial in Record Time!

176

Your Clinical Trial Site M&A Agreement is Exposing You to Risk

177

What Does ICH E6 R3 Say About Returning Data to Participants?

178

Navigating the Ongoing HHS Communication Freeze

179

Ordinary People Are Changing Medicine

180

Trump’s First 10 Days: The Impact on Clinical Trials

181

Selling a Business with Issues

182

Breaking Down GCP E6(R3)

183

AdvaMed 7 rules for Essential AI Innovation

184

Teva’s Case Should Shape Your Pharma Strategy

185

AI’s Impact on Healthcare: Liability, Ethics, and Responsibility

186

Four Types of Research related Grant Fraud

187

Defining Scope in Due Diligence Transactions

188

Clinical Trial Checklist

189

Presidential Changes and Impact on Drug Related Misinformation

190

Prep for Selling Your Company!

191

Top Tips for Starting a Clinical Trial Site

192

When Drug Reps Visit: Darshan Reacts

193

Is Pfizer competing with your pharmacy?

194

Talking to a Functional Medicine Doctor

195

Four Types of Research related Grant Fraud

196

Leveraging AI and RWD to Reshape Drug Trials!

197

DCTs in Oncology: Can They Work?

198

Marketing Due Diligence in Stem cell M&A Transactions

199

Why Are PBMs Blocking Your Meds? - Darshan reacts

200

Misleading Ads: Ad laws and Consumer Protection for Marketers

201

5 Common Clinical Trial Site Failures

202

Faster FDA Recalls

203

IRB Challenges and Updates for 2024

204

Is the Polio Vaccine Safe?

205

FDA blue print to discuss off label topics

206

Opportunities AI provides in Clinical Research

207

Telehealth and Biohacking: A Risky Combination

208

Is the FDA’s Response to AI Falling Behind?

209

Healthcare Is in Crisis: How do we fix it?

210

Will RFK Break Pharma?

211

Fake data in Clinical Trials

212

Darshan Fixes Big Pharma Misconceptions

213

How Trump’s Tariffs will Disrupt Clinical Trials and Drug Marketing?

214

Why China is Targeting Top Scientists!

215

Trump’s Bold Picks Shake Up Life Sciences

216

3 Regulatory Opportunities in Clinical Trials!

217

Don't Take Non-Prescription Ozempic or other Weight Loss Drugs

218

Clinical Trial Principal Investigator Duties in Clinical Trials

219

Supreme Court Redefined Pharma Marketing Rules

220

AI concerns in M&A for Life Sciences

221

Trump Teams Potential Changes to Healthcare

222

Can AI Rewrite the Rules of Clinical Trials?

223

Ad Promo Review in Pharma - How Far is Too Far?

224

Why Staff Training Problems are a liability for Your Clinical Trial site

225

Neuralink: Breakthrough or Marketing Hype?

226

Telehealth Compliance Crisis: DOJ exposes $2.75B Fraud!

227

Should You Go In-House or Outsource Your Advertising Compliance?

228

Research fraud tainting pharma per Nature Article

229

Influencers are NOT KOLs. Know your Needs!

230

AI and Clinical Trials: Faster Results, Bigger Risks?

231

Eli Lilly’s Unexpected Shift on Use of Mounjaro!

232

Are CROs Losing Relevance in the Age of DCTs?

233

Managing Risks in Life Science Mergers and Acquisitions with Strategic Insurance

234

Can a Pharmacist Override Your Doctor's Prescription?

235

FDA Concerns About AI’s impact on Good Clinical Practices

236

Patient Advocates Could Cost You Millions

237

Managing Risks in Life Sciences Mergers and Acquisitions

238

How do pharmacists’ read doctors’ cursive letters?

239

AI Data Ownership in Pharma

240

Role of Tech Transfer in Clinical trial agreements

241

Why are medicine names so complicated?

242

Fixing Congruency Reviews in 8 Minutes

243

The Dark Side of Med Device Kickbacks

244

Which Hair Loss Treatment Is Right for You?

245

Analyzing the Publication Rights Clause in CTAs

246

What Really Starts Pharmacy Investigations?

247

Is your clinical trial AI racist?

248

Another Pharmacy owner Jailed in Fraud Case

249

Navigating FDA's clinical trial expectations after approval

250

Legal Minute: Do dietary supplements interact with drugs?

251

How Expert Pharma Marketers Navigate Privacy

252

Hiring New Employees in PharmaTech Companies

253

3 Hidden Dangers of Telehealth Marketing

254

Why a food lawyer would stop your restaurant’s marketing?

255

Legal Minute: Why are there chemo drug shortages?

256

Are Pharma Giants Ignoring Clinical Trial Site Issues?

257

Why Adverse Events Go Unreported in Clinical Trials

258

Who are patient advocates?

259

Why Drug Accountability Matters in Clinical Trials

260

Legal Minute: What do I do if my med is on shortage?

261

5 reasons not to use AI in creating pharma marketing content

262

8 essential elements of a valid prescription

263

No more lawyers in PRC?

264

Legal Minute: 4 Ways to Get Unapproved Drugs Legally!

265

The 4 Building Blocks of Using AI in any Pharma Marketing Strategy

266

Legal Minute: Why Clinical Trials Are Right for You!

267

Why Clinical Researchers Are Flocking to MedSpas

268

Legal Minute: Why You Should Never Trust a Celebrity with Your Health

269

Essential tips for pharmacy shutdowns

270

Why Clinical Researchers Are Flocking to MedSpas

271

Legal Minute: 5 Surprising Benefits of Ozempic!

272

Who Owns AI Generated Content in Pharma?

273

Legal Minute: Why does my drug cost so much?

274

AI for Promotions in FDA-Regulated Industries

275

Legal Minute: Billion-Dollar Speaker Scheme!

276

Off-Label Risks: Compliance Matters Now More Than Ever

277

6 Must-Knows Before Buying a Drug or Device Company

278

Legal Minute: Are there chemo drug shortages?

279

Legal Minute: Don’t Ignore State Registrations

280

Legal Minute: 6 Crucial Mistakes in Informed Consent

281

Legal Minute: What is informed consent in clinical trials?

282

Stop Risky Ads: Class Actions Could Cost You

283

Legal Minute: How do drugs work?

284

5 Surprising Causes of Life Science Deal Failures

285

Legal Minute: Is pharma bribing your doctor?

286

Legal Minute: Drug Registrations that can’t be ignored

287

Legal Minute: Why do pharmacies take so long to fill prescriptions?

288

Legal Minute: 3 Steps to Avoid Food Recalls

289

Legal Minute: Are dietary supplements as good as drugs?

290

Legal Minute: Clinical Trial Record Retention Disasters

291

Legal Minute: Why is your medicine so expensive?

292

McKinsey’s 2030 vision: A challenge for medical affairs

293

Legal Minute: 3 must-do takeaways for collecting diversity data in clinical trials

294

Legal Minute: Are Brand and Generic Drugs Truly Different?

295

Legal Minute: Who's REALLY Responsible for a Clinical Trial Congruency review?

296

This Drug Ad is FULL of Red Flags (We Expose Them All!)

297

7 ways to challenge FDA’s regulation of LDTs

298

Legal Minute: eBay’s $59 Million Drug-Making Problem

299

Legal Minute: Neuralink is a Game-Changer: 3 Lessons You Can't Afford to Miss

300

Legal Minute: Off-label marketing not ok again?

301

Don't Become the Next Fraud Headline: Lawyer Reveals Compliance Traps

302

Legal Minute: 3 Insider Secrets for a Successful Medical Device Recall

303

Key elements of a successful congruency review for clinical trial agreements

304

Why Private Equity firms are betting big on clinical research sites

305

5 Ways to Legally Share Off-Label Information

306

DOJ's "Get Out of Jail Free" card for pharma and device mergers?

307

Legal Minute: 5 factors to get your digital speaker program approved

308

Legal Minute: Decoding the FDA's prescription drug use related software guidance

309

Congruency Review: The Game Changer

310

Legal Minute: 5 hacks to fast-track your speaker program reviews

311

Selecting your ideal subject recruitment partner

312

Your digital sales team’s success depends on these 5 compliance rules

313

Legal Minute: 3 FTC rules for winning comparative claims

314

The risks and rewards of Clinical Research as a Care Option

315

3 game changing ways the FDA says AI will transform drug development

316

Legal Minute: Comparative claim review by NAD

317

5 foolproof ways to get your digital speaker program approved

318

Legal Minute: Prepare your Cosmetics Company for 2024

319

How to get PRC to approve your ads quickly

320

Legal Minute: 4 Must Do's When Choosing a Predicate Device for Your 510(k)

321

Legal Minute: FDA's Vision for the Future of IT

322

Legal Minute: FTC announces major revamp in 2024 enforcement strategy

323

23andMe data breach: Is your genetic data the next big target for hackers?

324

Ultimate Guide for Clinical Trial Publishing Rights in Large Academic Centers | Istvan Fekete

325

FDA's off-label trap: 7 reasons for uncertainty

326

Legal Minute: 3 ways #pharmacies are fighting high generic drug prices!

327

Pharma Industry Secrets: The Surprising Truth About DEI | Celia Daniels

328

Case Study: Academic Research Center Misconduct

329

Legal Minute: FTC Cracking Down on AI- 3 Must-Know Tips to Stay Compliant

330

Project management as a clinical research game-changer

331

Legal Minute: 5 Must-Do’s for Virginia Tech’s FBRI to combat research fraud

332

Legal Minute: Pharmacy Closing Checklist: 7 Must Do's

333

FDA Approval for LDTs Made Easy

334

Legal Minute: Pharmacist fraudster found guilty

335

AI's Complex Role: Creator, Copycat or Both?

336

FDA warns 8 companies including Walgreens selling unapproved eye products

337

Why the FDA’s plan to use one pagers will fail

338

Supercharge your Marketing Approval Process based on these Concept Review Tips

339

Testosterone parties and unapproved biohacks: Is it worth the risk? #darshantalks

340

Generative AI…confidently spews BS!

341

Testosterone parties and unapproved biohacks: Is it worth the risk? #darshantalks

342

Research Fraudster Banned by the FDA

343

How does CTP regulate tobacco? | Micah Berman

344

60 second reveal: 3 Regulatory authorities that can make or break your pharma or device sale

345

Maximizing FDA meetings: Getting the best out of every encounter | Ashley Preston

346

The role of decentralized trials in the traditional landscape | Isaac Rodriguez- Chavez

347

The Essential Guide to 7 Types of Clinical Trial Agreements